A Most Favored National Policy for Pharma Drugs Makes Sense
"Most favored nation" pricing can help make America's pharmaceutical marketplace more competitive.
It is not surprising that President Trump issued a May 12, 2025 executive order, “Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients," which represents the administration’s efforts to lower prescription drug prices. This action uses what is known as “most favored nation” pricing to link the price of selected U.S. pharmaceutical drugs in America to countries where the same drugs are sold for less. The order extends beyond Medicare Part B drugs and will likely target lucrative expensive medications like GLP-1 drugs (known for weight management et al). Also targeted will be the ability of Big Pharma to set its own prices.
It is sensible both economically and politically.
As an economist, I believe that the marketplace is the best way to solve most pricing problems. Unfortunately, America’s pharmaceutical industry, and medical care in general, are not competitive marketplaces. Regulations, industry consolidation, and third-party insurance all lead to extraordinarily high prices for medications. Expensive to begin with, the cost of drug development has increased by a factor of 5 when accounting for costs of capital and failures. From 2008 to 2019, the ratio of R&D spending to total sales increased from 11.9% to 17.7%. Once launched though, the marginal cost of manufacturing most drugs is extraordinarily low. In many cases a single capsule costs only pennies to make. In a truly competitive market, where marginal revenue and marginal cost equate in the long run, many medicines would be extraordinarily inexpensive.
Economic Dynamism
.jpg)
London and the Architecture of Creative Growth
Preserving London's creative dynamism will require humility from policymakers and a commitment to keeping the city liveable.
Do Dynamic Societies Leave Workers Behind Economically?
We need a more dynamic economy that can help workers by allowing them to move where they can best use their skills.
.jpg)
Downtowns are dying, but we know how to save them
Even those who yearn to visit or live in a walkable, dense neighborhood are not going to flock to a place surrounded by a grim urban dystopia.
.jpeg)
.jpg)
Adam Smith’s The Wealth of Nations Turns 250
"On the Nature and Causes of the Wealth of Nations" was published this month in 1776.
AI Needs Consumer Choice, Not Bureaucratic Control
The regulatory approach treats consumer AI as a problem to be solved rather than as another service best left to a competitive, dynamic market to provide consumers with autonomy and choice.
